menu
    • menu
    [{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"Yisheng Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The alliance is aimed at co-developing a combination therapy of YS-ON-001\/002 and Tavo-201\/203 for cancer treatment.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Tavo-201","moa":"CD4+ T-Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tavotek Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tavotek Biotherapeutics \/ Yisheng Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Tavotek Bi.."},{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"Genmab","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tavotek Inks Research Pact with Genmab to Develop Bispecific Antibodies using Duobody Technology Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Bispecific antibodies","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Tavotek Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tavotek Biotherapeutics \/ Tavotek Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Tavotek Bi.."},{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"YuanBio Venture Capital","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tavotek Biotherapeutics Announces Completion of Round A1 and A2 Financing with over $20 Million Dollars","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series A Financing","leadProduct":"Tavo111","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tavotek Biotherapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Tavotek Biotherapeutics \/ YuanBio Venture Capital","highestDevelopmentStatusID":"4","companyTruncated":"Tavotek Bi.."}]

    Find Clinical Drug Pipeline Developments & Deals by Tavotek Biotherapeutics

    Menu

    Tavotek Biotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tavotek Biotherapeutics

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            Tavotek Biotherapeutics

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tavo111

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : YuanBio Venture Capital

                            Deal Size : $20.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Tavotek Biotherapeutics Announces Completion of Round A1 and A2 Financing with over $20 Million Do...

                            Details : The two rounds of financing will be used to accelerate the CMC production and IND filings of three antibody drugs (Tavo111, Tavo103, and Tavo101) developed by the company based on its TavoPrecise antibody...

                            Brand Name : Tavo111

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 22, 2021

                            Lead Product(s) : Tavo111

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : YuanBio Venture Capital

                            Deal Size : $20.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tavotek Biotherapeutics

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            Tavotek Biotherapeutics

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bispecific antibodies

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Recipient : Genmab

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Tavotek Inks Research Pact with Genmab to Develop Bispecific Antibodies using Duobody Technology P...

                            Details : The objective of the agreement is to develop a novel first-in-class immune-modulator bispecific antibody for auto-immune and inflammatory-related conditions, using DuoBody® technology, proprietary platfo...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 25, 2020

                            Lead Product(s) : Bispecific antibodies

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Recipient : Genmab

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tavotek Biotherapeutics

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            Tavotek Biotherapeutics

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YS-ON-001,YS-ON-002,Tavo-201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Yisheng Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            The alliance is aimed at co-developing a combination therapy of YS-ON-001/002 and Tavo-201/203 for...

                            Details : The objective of the alliance is to co-develop a combination therapy of involving Yisheng's & Tavotek's lead assets YS-ON-001/002 and Tavo-201/203 for cancer treatment.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 06, 2020

                            Lead Product(s) : YS-ON-001,YS-ON-002,Tavo-201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Yisheng Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth